Aventis Apidra Clears FDA; Launch Of Fast-Acting Insulin Awaits Delivery Pen
Executive Summary
Aventis will wait to launch the rapid-acting recombinant human insulin analog Apidra until after approval of the OptiClick pen delivery device
You may also be interested in...
Sanofi-Aventis Deal Means More Leverage With Managed Care
Sanofi's $65 bil. merger with Aventis will offer the combined entity additional negotiating clout with large U.S. drug purchasers, Exec VP-Operations Hanspeter Spek said during an April 26 conference call
Sanofi-Aventis Deal Means More Leverage With Managed Care
Sanofi's $65 bil. merger with Aventis will offer the combined entity additional negotiating clout with large U.S. drug purchasers, Exec VP-Operations Hanspeter Spek said during an April 26 conference call
Aventis Defense Against Sanofi: Strong Pipeline Or Irrational “Exubera-nce”?
Aventis is using the prospects of Genasense as its first line of defense against Sanofi's hostile takeover bid